Takayasu arteritis (TA), also known as aortoarteritis, often involves the middle aorta and manifests as middle aortic syndrome (MAS) [1]. Owing to persistent and severe hypertension attributed to aortic obstruction, patients with MAS caused by TA (TA-MAS) may develop ventricular hypertrophy. Moreover, patients with TA-MAS may even progress to heart failure (HF) [2], which has an incidence of 22.9 % [3]. Pharmacological based interventional therapy is commonly used to treat TA-MAS. However, few clinical studies have examined whether this strategy can stop or reverse ventricular hypertrophy and HF.
